The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Investigation of Intravenous Azithromycin Treatment Safety When Reducing Solvent for Intensive Care Unit Patients
|
|---|---|
| Published in |
Yakugaku Zasshi = Journal of Pharmaceutical Society of Japan, August 2015
|
| DOI | 10.1248/yakushi.15-00003 |
| Pubmed ID | |
| Authors |
Yuto Haruki, Hideharu Hagiya, Akiko Sakuma, Mai Haruki, Yasue Oka, Tetsuhiro Sugiyama, Yasuhiro Kawakami, Sachiyo Kondo |
| Abstract |
Intravenous azithromycin (AZM) was approved for use in December 2011 in Japan. In general, intravenous AZM injections are diluted to 1 mg/mL, with a total infusion volume of 500 mL to avoid phlebitis. Patients in intensive care units (ICUs) require small infusion volumes. We retrospectively evaluated the total AZM infusion volume in 65 ICU patients receiving AZM treatment from December 2011 to August 2014. Thirteen patients (20.0%) received a reduced volume [100 mL (5 mg/mL) or 250 mL (2 mg/mL)] using an infusion pump over 2 h. No peripheral phlebitis was observed in any patient. Based on this result, it is assumed that AZM can be safely administered to ICU patients even though the volume of solvent is reduced. AZM is widely recommended for the treatment of community-acquired respiratory infections and is used in patients with severe infections. Further investigation is required in additional patients to understand the effects of AZM volume reduction in greater detail. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 20% |
| Student > Master | 2 | 20% |
| Student > Doctoral Student | 1 | 10% |
| Professor | 1 | 10% |
| Unknown | 4 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 3 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 10% |
| Business, Management and Accounting | 1 | 10% |
| Medicine and Dentistry | 1 | 10% |
| Unknown | 4 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2023.
All research outputs
#16,039,804
of 26,150,873 outputs
Outputs from Yakugaku Zasshi = Journal of Pharmaceutical Society of Japan
#1,341
of 1,977 outputs
Outputs of similar age
#141,014
of 277,965 outputs
Outputs of similar age from Yakugaku Zasshi = Journal of Pharmaceutical Society of Japan
#2
of 11 outputs
Altmetric has tracked 26,150,873 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,977 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,965 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.